|
顯示項目 711231-711240 / 2346275 (共234628頁)
<< < 71119 71120 71121 71122 71123 71124 71125 71126 71127 71128 > >>
每頁顯示[10|25|50]項目
| 國立成功大學 |
2023 |
Real-World Analyses of the Treatment Conditions in Patients Initiating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor in Taiwan
|
Lin, P.-L.;Wu, Y.-W.;Lin, C.-F.;Yeh, H.-I.;Chang, W.-T.;Charng, M.-J.;Huang, P.-H.;Lin, C.-C.;Lin, T.-H.;Lin, W.-W.;Hsieh, I.-C.;Kuo, F.-Y.;Chen, Chen C.-P.;Li, Y.-H. |
| 國立成功大學 |
2024-10 |
Real-World Analysis of GLP-1 Receptor Agonists and Lung Cancer Risk in Treatment-Naive Type 2 Diabetes: Potential Impact of Obesity and Gender
|
Song;J;Daylan;Cali, A. E.;Chi;K, -Y.;Chang;Y;Memon;R, S.;Lee;J;Ahn;J;Chiang;C, -H.;Cheng;H |
| 臺大學術典藏 |
2021-05-24T07:20:23Z |
Real-world anti-viral treatment decisions among chronic hepatitis C patients in Taiwan: The INITIATE study
|
CHEN-HUA LIU; Yu M.-L.; Peng C.-Y.; Hsieh T.-Y.; Huang Y.-H.; Su W.-W.; Cheng P.-N.; Lin C.-L.; Lo C.-C.; Chen C.-Y.; Chen J.-J.; Ma Q.; Brooks-Rooney C.; Kao J.-H. |
| 臺大學術典藏 |
2021-09-04T05:16:51Z |
Real-world anti-viral treatment decisions among chronic hepatitis C patients in Taiwan: The INITIATE study
|
Liu C.-H.; Yu M.-L.; Peng C.-Y.; Hsieh T.-Y.; Huang Y.-H.; Su W.-W.; Cheng P.-N.; Lin C.-L.; Lo C.-C.; Chen C.-Y.; Chen J.-J.; Ma Q.; Brooks-Rooney C.; JIA-HORNG KAO |
| 國立成功大學 |
2019 |
Real-world anti-viral treatment decisions among chronic hepatitis C patients in Taiwan: The INITIATE study
|
Liu, C.-H.;Yu, M.-L.;Peng, C.-Y.;Hsieh, T.-Y.;Huang, Y.-H.;Su, W.-W.;Cheng, P.-N.;Lin, C.-L.;Lo, C.-C.;Chen, Chen C.-Y.;Chen, J.-J.;Ma, Q.;Brooks-Rooney, C.;Kao, J.-H. |
| 國立成功大學 |
2023 |
Real-world bleeding outcomes and product utilization in people with severe-type hemophilia A before and after switching to extended half-life rFVIIIFc prophylaxis therapy
|
Chang, Chang C.-Y.;Lai, S.-W.;Cheng, M.-M.;Ku, J.-T.;Hu, S.-H.;Liu, Y.-L.;Tsai, J.-R.;Tsai, C.-H.;Cheng, Cheng C.-N.;Chen, Y.-C. |
| 嘉南藥理大學 |
2022 |
Real-World Comparative Effectiveness of Nivolumab versus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma
|
Kuo, Hsin-Yu; Han, Meng-Zhi; Liao, Chih-Hsiang; Lin, Yih-Jyh; Wang, Chung-Teng; Chen, Shang-Hung; Chang, Ting-Tsung; Chen, Po-Jun; Lin, Sheng-Hsiang; Chen, Chiung-Yu; Chuang, Chiao-Hsiung; Wu, I-Chin; Wu, Juei-Seng; Hong, Tzu-Chun; Hsieh, Ming-Tsung; Lee, Yang-Cheng; Wu, Hung-Tsung; Tsai, Hong-Ming |
| 國家衛生研究院 |
2022-10-23 |
Real-world comparative effectiveness of nivolumab versus pembrolizumab in patients with unresectable hepatocellular carcinoma
|
Kuo, HY;Han, MZ;Liao, CH;Lin, YJ;Wang, CT;Chen, SH;Chang, TT;Chen, PJ;Lin, SH;Chen, CY;Chuang, CH;Wu, IC;Wu, JS;Hong, TC;Hsieh, MT;Lee, YC;Wu, HT;Tsai, HM |
| 國立成功大學 |
2022-11 |
Real-World Comparative Effectiveness of Nivolumab versus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma
|
Kuo;Hsin-Yu;Han;Meng-Zhi;Liao;Chih-Hsiang;Lin;Yih-Jyh;Wang;Chung-Teng;Chen;Shang-Hung;Chang;Ting-Tsung;Chen;Po-Jun;Lin;Sheng-Hsiang;Chen;Chiung-Yu;Chuang;Chiao-Hsiung;Wu;I-Chin;Wu;Juei-Seng;Hong;Tzu-Chun;Hsieh;Ming-Tsung;Lee;Yang-Cheng;Wu;Hung-Tsung;Tsai;Hong-Ming |
| 國立成功大學 |
2022-11 |
Real-world comparative effectiveness of nivolumab versus pembrolizumab in patients with unresectable hepatocellular carcinoma
|
郭欣瑜; Kuo, Shi-Yu; Kuo, Hsin-Yu;Han, Meng-Zhi;Liao, Chih-Hsiang;Lin, Yih-Jyh;Wang, Chung-Teng;Chen, Shang-Hung;Chang, Ting-Tsung;Chen, Po-Jun;Lin, Sheng-Hsiang;Chen, Chiung-Yu;Chuang, Chiao-Hsiung;Wu, I-Chin;Wu, Juei-Seng;Hong, Tzu-Chun;Hsieh, Ming-Tsung;Lee, Yang-Cheng;Wu, Hung-Tsung;Tsai, Hong-Ming |
顯示項目 711231-711240 / 2346275 (共234628頁)
<< < 71119 71120 71121 71122 71123 71124 71125 71126 71127 71128 > >>
每頁顯示[10|25|50]項目
|
